Table 3.
Clinical studies analyzing characteristics and survival of patients diagnosed with brain metastases originating from gastric cancer.
| Inc | n | Age (Years) | Male | ECM | BM > 1 | Resection | OS (Months) | OS Resection (Months) | Reference |
|---|---|---|---|---|---|---|---|---|---|
| 0.7% | 24 | 53 | 75% | 88% | 55% | 21% | 2.4 | 12.5 | [33] |
| 0.2% | 11 | 44 | 54% | n/a | n/a | 0% | 1.4–2.2 | n/a | [34] |
| 0.5% | 11 | 55 | 82% | 20% | 55% | 27% | 2.7 | 6 | [35] |
| n/a | 11 | 61 | 64% | 82% | 45% | 18% | 27.7 | 45.5 | [36] |
| n/a | 56 | 56 | 79% | 91% | 55% | n/a | 2.1–9.3 | n/a | [37] |
Inc = Incidence of brain metastases in the respective study; n = number of patients enrolled in the study; Male = Percentage of male patients of the patient cohort; ECM = percentage of patients diagnosed with extra-cranial metastases; BM > 1 = percentage of patients diagnosed with more than one brain metastases; Resection = percentage of patients that received surgical resection of brain metastases; OS = median survival of all patient diagnosed with brain metastases within the respective study; OS Resection = median survival of the patients who received surgical resection of brain metastases; n/a = data not available.